193 related articles for article (PubMed ID: 33842645)
1. Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report.
Chen Z; Zhu F; Li C; Li J; Cheng B; Xiong S; Zhong R; Liang W; He J
Ann Transl Med; 2021 Mar; 9(5):424. PubMed ID: 33842645
[TBL] [Abstract][Full Text] [Related]
2. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Jamme P; Fernandes M; Copin MC; Descarpentries C; Escande F; Morabito A; Grégoire V; Jamme M; Baldacci S; Tulasne D; Kherrouche Z; Cortot AB
J Thorac Oncol; 2020 May; 15(5):741-751. PubMed ID: 32169477
[TBL] [Abstract][Full Text] [Related]
5. Current and future treatment options for
Hong L; Zhang J; Heymach JV; Le X
Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
7. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
9. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
Tian J; Lin Z; Chen Y; Fu Y; Ding Z
Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
Kato Y; Yamamoto G; Watanabe Y; Yamane Y; Mizutani H; Kurimoto F; Seike M; Gemma A; Akagi K; Sakai H
Int J Clin Oncol; 2021 Jun; 26(6):1065-1072. PubMed ID: 33660106
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
15. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
[TBL] [Abstract][Full Text] [Related]
16. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
Minne RL; Luo NY; Traynor AM; Huang M; DeTullio L; Godden J; Stoppler M; Kimple RJ; Baschnagel AM
Clin Lung Cancer; 2024 May; ():. PubMed ID: 38852006
[TBL] [Abstract][Full Text] [Related]
17. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
Front Oncol; 2021; 11():649766. PubMed ID: 34249687
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
19. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G; Trillo Aliaga P; Attili I; Del Signore E; Corvaja C; Corti C; Uliano J; Passaro A; de Marinis F
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835473
[TBL] [Abstract][Full Text] [Related]
20. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.
Mahrous M; Omar Jebriel A; Allehebi A; Shafik A; El Karak F; Venturini F; Alhusaini H; Meergans M; Ali Nahit Sendur M; Ouda M; Al-Nassar M; Kilickap S; Al Turki S; Al-Fayea T; Abdel Kader Y
Cureus; 2023 Jul; 15(7):e41992. PubMed ID: 37492039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
